Literature DB >> 8301544

Pentoxifylline and meclofenamic acid treatment reduces clinical manifestations in a murine model of AIDS.

I Stadler1, K C Chadha, S Nakeeb, C Toumbis, J Butsch, N Mathur, F Munschauer, A Vladutiu, S K Satchidanand, J L Ambrus.   

Abstract

C57/BL/6 mice infected with LP-BM5 MuLV virus developed an AIDS-like disease (MAIDS) with splenomegaly, leukopenia, thrombocytopenia, anemia, decreased numbers of helper/inducer and suppressor/cytotoxic T-cells and decreased production of interferon alpha. We have shown previously that HIV-associated Kaposi's sarcoma tissue contains high levels of prostaglandin E2 (PgE2), and this inhibits interferon synthesis through a cAMP-dependent second-messenger process. In this study we treated groups of MAIDS-infected mice with combinations of pentoxifylline, an agent which increases cAMP and inhibits phosphodiesterases, and sodium meclofenamic acid, a PgE2 inhibitor. Treated mice showed: 1) significantly higher total leukocyte and platelet counts, 2) higher total L3T4+ (helper/inducer) and Lyt-2+ (suppressor-cytotoxic) T-cell population. Pathologic examination also showed significantly less hepatosplenomegaly and lymphadenopathy in animals treated with pentoxifylline and meclofenamic acid. Partly, PgE2-induced suppression of interferon alpha production may mediate expression of retrovirus infection in this murine model of AIDS.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8301544

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  2 in total

1.  Alpha/beta interferons increase host resistance to murine AIDS.

Authors:  J K Heng; P Price; C M Lai; M W Beilharz
Journal:  J Virol       Date:  1996-07       Impact factor: 5.103

2.  Interleukin (IL)-4-independent immunoglobulin class switch to immunoglobulin (Ig)E in the mouse.

Authors:  R A Morawetz; L Gabriele; L V Rizzo; N Noben-Trauth; R Kühn; K Rajewsky; W Müller; T M Doherty; F Finkelman; R L Coffman; H C Morse
Journal:  J Exp Med       Date:  1996-11-01       Impact factor: 14.307

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.